Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | THRB | P10828 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | PRKCA | P17252 | 1/20 | 0.31 |
| ▸ | CA12 | O43570 | 1/20 | 0.30 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
| ▸ | CA9 | Q16790 | 1/20 | 0.30 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2533297 | 1.00 | ALDH1A1 (0.38) | ALDH1A1TDP1MEN1THRBHTT | |
| SCHEMBL2527273 | 0.98 | ALDH1A1 (0.39) | ALDH1A1TDP1HTTMAPTCA12 | |
| SCHEMBL2527386 | 0.91 | ALDH1A1 (0.33) | ALDH1A1MEN1THRBHTTKMT2A | |
| SCHEMBL9813412 | 0.91 | LMNA (0.39) | ALDH1A1MEN1THRBHTTKMT2A | |
| SCHEMBL2533550 | 0.91 | ALDH1A1 (0.33) | ALDH1A1MEN1THRBHTTKMT2A | |
| SCHEMBL10878928 | 0.91 | LMNA (0.39) | ALDH1A1MEN1THRBHTTKMT2A | |
| SCHEMBL2523631 | 0.91 | ALDH1A1 (0.41) | ALDH1A1TDP1CA12CA1CA2 | |
| SCHEMBL2528031 | 0.88 | LMNA (0.35) | ALDH1A1 | |
| SCHEMBL31086378 | 0.88 | ALDH1A1 (0.40) | ALDH1A1TDP1MEN1THRBHTT | |
| SCHEMBL9945701 | 0.88 | ALDH1A1 (0.40) | ALDH1A1TDP1MEN1THRBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8461135-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2013-06-11 | — | — | US | claimed |
| US-8039450-B2 | Boron-containing small molecules as anti-inflammatory agents | ANACOR PHARMACEUTICALS, INC. (US) | 2011-10-18 | — | — | US | claimed |
| EP-1910340-B1 | INDAZOLECARBOXAMIDE DERIVATIVES AS 5HT4 RECEPTOR AGONISTS | PFIZER (US) | 2009-11-18 | — | — | EP | disclosed |
| US-RE39088-E1 | Amide compounds and use of the same | JAPAN TOBACCO, INC. (JP) | 2006-05-02 | — | — | US | disclosed |
| WO-2005082459-A2 | METHOD OF DECREASING BLOOD CELLS | JAPAN TOBACCO INC. (JP) | 2005-09-09 | — | — | WO | disclosed |
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | JAPAN TOBACCO INC. (JP) | 2005-08-25 | — | — | US | disclosed |
| EP-0849256-B1 | AMIDE COMPOUNDS AND USE OF THE SAME | JAPAN TOBACCO INC (JP) | 2005-06-08 | — | — | EP | disclosed |
| EP-1304322-A2 | Carboxylic acid compound and use thereof | Japan Tobacco Inc. (JP) | 2003-04-23 | — | — | EP | disclosed |
| US-6420561-B1 | Amide compounds and use thereof | JAPAN TOBACCO INC. (JP) | 2002-07-16 | — | — | US | disclosed |
| US-6174887-B1 | Amide compounds and use of the same | JAPAN TOBACCO INC. (JP) | 2001-01-16 | — | — | US | disclosed |
| EP-0849256-A1 | AMIDE COMPOUNDS AND USE OF THE SAME | Japan Tobacco Inc. (JP) | 1998-06-24 | — | — | EP | disclosed |
| EP-0330108-B1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO (JP) | 1995-12-27 | — | — | EP | disclosed |
| US-5081237-A | Chemical intermediates for bactericides | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1992-01-14 | — | — | US | disclosed |
| US-4923857-A | CARBAPENICILLINS | FUJISAWA PHARMACEUTICAL COMPANY, LTD. (JP) | 1990-05-08 | — | — | US | disclosed |
| EP-0330108-A1 | 3-Alkenyl-1-azabicyclo(3.2.0)hept-2-ene-2-carboxylic acid compounds | FUJISAWA PHARMACEUTICAL CO., LTD. (JP) | 1989-08-30 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050187221-A1 | Method of treating ischemia reperfusion injury | TNF, IL1B, TNNI3 | ALDH1A1 358/4885TDP1 4141/4885MEN1 4862/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.